Recent 13F filings as of December 2025 show that 117 institutional investors hold a position in CytomX Therapeutics, Inc. (NASDAQ:CTMX).
| Owner Name | Date | Shares Held | Change (QoQ) | Change (%) | Value (USD) |
|---|---|---|---|---|---|
| FMR LLC | 31 Dec, 2025 | 24,688,109 | 9,291,909 | 60.35% | $105,171,344.00 |
| VR Adviser, LLC | 31 Dec, 2025 | 15,561,500 | 0 | 0.00% | $66,291,990.00 |
| PERCEPTIVE ADVISORS LLC | 31 Dec, 2025 | 9,680,185 | 0 | 0.00% | $41,237,588.00 |
| Kynam Capital Management, LP | 31 Dec, 2025 | 8,966,077 | 5,319,574 | 145.88% | $38,195,488.00 |
| VANGUARD GROUP INC | 31 Dec, 2025 | 8,475,584 | -472,223 | -5.28% | $36,105,988.00 |
| Commodore Capital LP | 31 Dec, 2025 | 7,692,300 | 0 | 0.00% | $32,769,198.00 |
| Point72 Asset Management, L.P. | 31 Dec, 2025 | 5,189,538 | 1,120,963 | 27.55% | $22,107,432.00 |
| STATE STREET CORP | 31 Dec, 2025 | 5,140,931 | 4,495,949 | 697.07% | $21,900,366.00 |
| ADAR1 Capital Management, LLC | 31 Dec, 2025 | 4,282,769 | 237,355 | 5.87% | $18,244,596.00 |
| BAKER BROS. ADVISORS LP | 31 Dec, 2025 | 4,250,826 | 0 | 0.00% | $18,108,519.00 |
| BALYASNY ASSET MANAGEMENT L.P. | 31 Dec, 2025 | 3,872,202 | -40,879 | -1.04% | $16,495,581.00 |
| Financial Engines Advisors L.L.C. | 31 Dec, 2025 | 3,828,717 | 2,447,360 | 177.17% | $16,310,334.00 |
| BlackRock, Inc. | 31 Dec, 2025 | 3,669,393 | 1,287,481 | 54.05% | $15,631,615.00 |
| ORBIMED ADVISORS LLC | 31 Dec, 2025 | 3,525,650 | -4,935,850 | -58.33% | $15,019,269.00 |
| Vivo Capital, LLC | 31 Dec, 2025 | 2,884,615 | 0 | 0.00% | $12,288,460.00 |
| Eversept Partners, LP | 31 Dec, 2025 | 2,507,090 | 2,507,090 | 0.00% | $10,680,203.00 |
| GOLDMAN SACHS GROUP INC | 31 Dec, 2025 | 2,460,944 | 2,013,191 | 449.62% | $10,483,622.00 |
| Woodline Partners LP | 31 Dec, 2025 | 2,337,005 | 0 | 0.00% | $9,955,641.00 |
| TWO SIGMA INVESTMENTS, LP | 31 Dec, 2025 | 1,560,755 | 831,057 | 113.89% | $6,648,816.00 |
| GEODE CAPITAL MANAGEMENT, LLC | 31 Dec, 2025 | 1,525,666 | -43,632 | -2.78% | $6,502,652.00 |